Hypoglycemic Response to Dorzagliatin in a Patient With GCK-MODY.
Diabetes Care
; 47(7): 1140-1142, 2024 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-38691834
ABSTRACT
OBJECTIVE:
Metformin, insulin, and insulin secretagogues do not alter HbA1c levels in glucokinase maturity-onset diabetes of the young (GCK-MODY). However, the efficacy of the new hypoglycemic drugs on GCK-MODY remains unclear. RESEARCH DESIGN ANDMETHODS:
We describe a case of GCK-MODY with unchanged blood glucose under different therapies during an 8 years' follow-up. His HbA1c and biochemical indices under different hypoglycemic treatments were recorded.RESULTS:
Oral glucose-lowering drugs, including thiazolidinediones, dipeptidyl peptidase 4 inhibitor, α-glucosidase inhibitor, and sodium-glucose cotransporter 2 inhibitor that had not been evaluated previously, did not improve the HbA1c level in this patient. However, the glucokinase activator dorzagliatin effectively and safely lowered his HbA1c level.CONCLUSIONS:
Dorzagliatin was effective and safe in this patient with GCK-MODY, providing potential application prospects for precise treatment of GCK-MODY with dorzagliatin.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Hypoglycemic Agents
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Diabetes Care
Year:
2024
Document type:
Article